Tyrosine kinase domain mutations of EGFR gene in head and neck squamous cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Epidermal growth factor receptor (EGFR) is frequently altered in cancers like head and neck squamous cell carcinoma (HNSCC).
• EGFR serves as a key molecular target for cancer therapies, including monoclonal antibodies and tyrosine kinase (TK) inhibitors.

Purpose of the Study:

• To investigate the spectrum of mutations within exons 18, 19, 20, and 21 of the EGFR gene in HNSCC patients.
• To identify specific EGFR mutations and their prevalence in the HNSCC cohort.

Main Methods:

• Retrospective analysis of 47 confirmed HNSCC cases.
• Detection of EGFR TK domain mutations (exons 18-21) using Scorpion® chemistry and ARMS® technologies via real-time polymerase chain reaction (Rotor-Gene Q).

Main Results:

• EGFR-TK domain mutations were identified in 57% of HNSCC tumors.
• The study reported four cases of T790M mutations, a novel finding in HNSCC.
• Predominant mutations included L861Q (exon 21, 21%), exon 20 insertions (19%), and exon 19 deletions (17%).
• EGFR mutation status significantly correlated with higher tumor grade (P=0.026) and advanced stage (P=0.034).

Conclusions:

• The high frequency of EGFR-TK domain mutations, including the T790M variant, in HNSCC suggests potential therapeutic implications.
• Identifying these mutations may help optimize treatment strategies and improve patient prognosis in HNSCC.